Skip to main content


Doses of psilocybin, provided in combination with supporting psychotherapy, was found to produce significant reductions in symptoms of major depression in a study conducted by researchers at Johns Hopkins University.
The use of MDMA-assisted psychotherapy for the treatment of PTSD could receive final approval by the FDA by 2022, Rick Doblin, PhD, of the Multidisciplinary Association for Psychedelic Studies told Psych Congress 2020 preconference attendees.
Psych Congress cochair Charles Raison, MD, a leading researcher in the field of immune-brain interactions, explains how increased inflammation may affect response to psychotherapy.
As psychotherapy continues to evolve, the challenge now is to rebrand and reposition the powerful healthcare resource it has become.
Our field can hardly rescue primary care, but we can help it regain its proud tradition by reinforcing the importance of a comprehensive focus on health and illness.
Back to Top